ODAK
Orphan Drug for Acanthamoeba Keratitis
| Coordinatore | UNIVERSITE DE ROUEN
Organization address
address: RUE THOMAS BECKET 1 MONT SAINT AIGNAN contact info |
| Nazionalità Coordinatore | France [FR] |
| Totale costo | 5˙571˙493 € |
| EC contributo | 4˙050˙255 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2012-INNOVATION-1 |
| Funding Scheme | CP-FP |
| Anno di inizio | 2012 |
| Periodo (anno-mese-giorno) | 2012-12-01 - 2017-11-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
UNIVERSITE DE ROUEN
Organization address
address: RUE THOMAS BECKET 1 MONT SAINT AIGNAN contact info |
FR (MONT SAINT AIGNAN CEDEX) | coordinator | 273˙800.00 |
| 2 |
PSR Group BV
Organization address
address: Planetenweg 5 contact info |
NL (HOOFDDORP) | participant | 2˙437˙169.00 |
| 3 |
S.I.F.I. SOCIETA INDUSTRIA FARMACEUTICA ITALIANA SPA
Organization address
address: VIA ERCOLE PATTI 36 LAVINAIO 36 contact info |
IT (ACI SANT ANTONIO CT) | participant | 716˙503.00 |
| 4 |
CERATIUM LIMITED
Organization address
address: HOLLAND ROAD 41 contact info |
UK (WALLASEY) | participant | 271˙680.00 |
| 5 |
RESEARCH TOXICOLOGY CENTRE - SPA
Organization address
address: VIA TITO SPERI 12/14 contact info |
IT (POMEZIA (Roma)) | participant | 233˙353.00 |
| 6 |
MOORFIELDS EYE HOSPITAL NHS FOUNDATION TRUST
Organization address
address: City Road 162 contact info |
UK (LONDON) | participant | 117˙750.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'This project will undertake preclinical and clinical research of the Orphan Drug Polihexanide (PHMB). The main objective is to provide a safe and effective drug for the treatment of the rare ocular disease Acanthamoeba keratitis (AK) tested according to international regulatory standards. This debilitating infectious disease is caused by a free living protozoan which, in the absence of treatment, can have catastrophic consequences such as severe pain, visual loss and eye enucleation. There are no approved drugs to treat this disease. After Orphan Drug Designation Protocol Assistance was requested from the European Medicines Agency on our drug development research plan. The proposed protocol incorporates the EMA advice and will include a non-clinical phase, a double-blind placebo controlled Phase I trial and a randomised double-blind, active controlled, parallel groups Phase 3 study (efficacy and safety therapeutic confirmatory study). The primary deliverables will be: 1) experimental scientific evidence on the quality, safety and efficacy of PHMB to provide the basis for a Marketing Authorisation within 5 years; 2) recommendations aiming to improve clinical practices in the management of AK based on the efficacy and safety evidence. ODAK is an industry led project mobilising the critical mass of industrial, pharmaceutical and academic expertise. needed to develop and optimise therapeutic approaches to alleviate the severe negative impacts of AK on the health and quality of life of patients. In particular, through identifying optimal PHMB formulations and recommending the best dose-benefit treatment regimes. ODAK directly contributes to the International Rare Diseases Research Consortium goal towards 200 new therapies. An estimated 95% of the total estimated EU contribution to the project will go to industrial partners (of this 32% goes to SMEs). The industrial strength assures a rapid translation of research to market application.'